Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).
2018 ◽
Vol 36
(15_suppl)
◽
pp. 7033-7033
◽
2014 ◽
Vol 20
(9)
◽
pp. 1369-1374
◽